Investigational drugs in phase I and phase II clinical trials for hereditary angioedema

References

• Osler W. Hereditary angio-neurotic Œdema. Am J Med Sci. 1888;95(4):362–367.
   Google Scholar
• Donaldson VH, Evans RR. A biochemical abnormality in herediatry angioneurotic edema: absence of serum inhibitor of C’ 1-esterase. PubMed PMID: 14046003. Am J Med. 1963 Jul;35:37–44.
   PubMed Web of Science ®Google Scholar
• Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014 May;69(5):602–616. PubMed PMID: 24673465.
   PubMed Web of Science ®Google Scholar
• Farkas H, Veszeli N, Kajdacsi E, et al. “Nuts and Bolts” of laboratory evaluation of angioedema. Clin Rev Allergy Immunol. 2016 Oct;51(2):140–151. PubMed PMID: 27142368.
   PubMed Web of Science ®Google Scholar
• Rosen FS, Pensky J, Donaldson V, et al. Hereditary angioneurotic edema: two genetic variants. Science. 1965 May 14;148(3672):957–958. PubMed PMID: 14277836.
   PubMed Web of Science ®Google Scholar
• Tosi M, Stoppa-Lyonnet D, Carter P, et al. Molecular defects of the C1-inhibitor gene in hereditary angioedema. Behring Inst Mitt. 1989 Jul;(84):173–179. PubMed PMID: 2572212.
   PubMedGoogle Scholar
• Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun. 2006 May 19;343(4):1286–1289. PubMed PMID: 16638441. DOI:10.1016/j.bbrc.2006.03.092
   PubMed Web of Science ®Google Scholar
• Bafunno V, Firinu D, D’Apolito M, et al. Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema. J Allergy Clin Immunol. PubMed PMID: 28601681 Jun 08 2017. 10.1016/j.jaci.2017.05.020.
   PubMedGoogle Scholar
• Bork K, Wulff K, Steinmuller-Magin L, et al. Hereditary angioedema with a mutation in the plasminogen gene. Allergy. PubMed PMID: 28795768 Aug 10 2017. 10.1111/all.13270.
   Google Scholar
• Csuka D, Veszeli N, Varga L, et al. The role of the complement system in hereditary angioedema. Mol Immunol. 2017 Sep;89:59–68. PubMed PMID: 28595743. DOI:10.1016/j.molimm.2017.05.020
   PubMed Web of Science ®Google Scholar
• Kaplan AP, Joseph K. Complement, kinins, and hereditary angioedema: mechanisms of plasma instability when C1 inhibitor is absent. Clin Rev Allergy Immunol. 2016 Oct;51(2):207–215. PubMed PMID: 27273087. DOI:10.1007/s12016-016-8555-6
   PubMed Web of Science ®Google Scholar
• Nussberger J, Cugno M, Cicardi M, et al. Local bradykinin generation in hereditary angioedema. J Allergy Clin Immunol. 1999 Dec;104(6):1321–1322. PubMed PMID: 10589018.
   PubMed Web of Science ®Google Scholar
• Han ED, MacFarlane RC, Mulligan AN, et al. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest. 2002 Apr;109(8):1057–1063. PubMed PMID: 11956243; PubMed Central PMCID: PMC150945. DOI:10.1172/JCI14211
   PubMed Web of Science ®Google Scholar
• Brackertz D, Kueppers F. Hereditary angioneurotic oedema. Lancet. 1973 Sep 22;2(7830):680. PubMed PMID: 4125654.
   PubMed Web of Science ®Google Scholar
• Gelfand JA, Sherins RJ, Alling DW, et al. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med. 1976 Dec 23;295(26):1444–1448. PubMed PMID: 792688. DOI:10.1056/NEJM197612232952602
   PubMed Web of Science ®Google Scholar
• Cicardi M, Agostoni A. Hereditary angioedema. N Engl J Med. 1996 Jun 20;334(25):1666–1667. PubMed PMID: 8628365. DOI:10.1056/NEJM199606203342510
   PubMed Web of Science ®Google Scholar
• Caballero T, Aygoren-Pursun E, Bygum A, et al. The humanistic burden of hereditary angioedema: results from the burden of illness study in Europe. Allergy Asthma Proc. 2014 Jan-Feb;35(1):47–53. PubMed PMID: 24268449. DOI:10.2500/aap.2013.34.3685
   PubMed Web of Science ®Google Scholar
• Pappalardo E, Zingale LC, Cicardi M. Increased expression of C1-inhibitor mRNA in patients with hereditary angioedema treated with danazol. Immunol Lett. 2003 May 01;86(3):271–276. PubMed PMID: 12706530.
   PubMed Web of Science ®Google Scholar
• Drouet C, Desormeaux A, Robillard J, et al. Metallopeptidase activities in hereditary angioedema: effect of androgen prophylaxis on plasma aminopeptidase P. J Allergy Clin Immunol. 2008 Feb;121(2):429–433. PubMed PMID: 18158172; PubMed Central PMCID: PMC4126900. DOI:10.1016/j.jaci.2007.10.048
   PubMed Web of Science ®Google Scholar
• Farkas H, Zotter Z, Csuka D, et al. Short-term prophylaxis in hereditary angioedema due to deficiency of the C1-inhibitor–a long-term survey. Allergy. 2012 Dec;67(12):1586–1593. PubMed PMID: 23025435. DOI:10.1111/all.12032
   PubMed Web of Science ®Google Scholar
• Cicardi M, Bergamaschini L, Cugno M, et al. Long-term treatment of hereditary angioedema with attenuated androgens: a survey of a 13-year experience. J Allergy Clin Immunol. 1991 Apr;87(4):768–773. PubMed PMID: 2013670.
   PubMed Web of Science ®Google Scholar
• Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol. 2008 Feb;100(2):153–161. PubMed PMID: 18320917. DOI:10.1016/S1081-1206(10)60424-3
   PubMed Web of Science ®Google Scholar
• Fust G, Farkas H, Csuka D, et al. Long-term efficacy of danazol treatment in hereditary angioedema. Eur J Clin Invest. 2011 Mar;41(3):256–262. PubMed PMID: 20955212. DOI:10.1111/j.1365-2362.2010.02402.x
   PubMed Web of Science ®Google Scholar
• Farkas H, Martinez-Saguer I, Bork K, et al. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency. Allergy. 2017 Feb;72(2):300–313. PubMed PMID: 27503784; PubMed Central PMCID: PMC5248622.
   PubMed Web of Science ®Google Scholar
• Caballero T, Farkas H, Bouillet L, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol. 2012 Feb;129(2):308–320. PubMed PMID: 22197274.
   PubMed Web of Science ®Google Scholar
• Frank MM, Sergent JS, Kane MA, et al. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. N Engl J Med. 1972 Apr 13;286(15):808–812. PubMed PMID: 4551861. DOI:10.1056/NEJM197204132861503
   PubMed Web of Science ®Google Scholar
• Kleniewski J, Blankenship DT, Cardin AD, et al. Mechanism of enhanced kinin release from high molecular weight kininogen by plasma kallikrein after its exposure to plasmin. J Lab Clin Med. 1992 Jul;120(1):129–139. PubMed PMID: 1535355.
   PubMed Web of Science ®Google Scholar
• Van Geffen M, Cugno M, Lap P, et al. Alterations of coagulation and fibrinolysis in patients with angioedema due to C1-inhibitor deficiency. Clin Exp Immunol. 2012 Mar;167(3):472–478. PubMed PMID: 22288590; PubMed Central PMCID: PMC3374279. DOI:10.1111/j.1365-2249.2011.04541.x
   PubMed Web of Science ®Google Scholar
• Zanichelli A, Vacchini R, Badini M, et al. Standard care impact on angioedema because of hereditary C1 inhibitor deficiency: a 21-month prospective study in a cohort of 103 patients. Allergy. 2011 Feb;66(2):192–196. PubMed PMID: 21039598. DOI:10.1111/j.1398-9995.2010.02433.x
   PubMed Web of Science ®Google Scholar
• Saule C, Boccon-Gibod I, Fain O, et al. Benefits of progestin contraception in non-allergic angioedema. Clin Exp Allergy. 2013 Apr;43(4):475–482. PubMed PMID: 23517043. DOI:10.1111/cea.12055
   PubMed Web of Science ®Google Scholar
• Farkas H, Jakab L, Temesszentandrasi G, et al. Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy. J Allergy Clin Immunol. 2007 Oct;120(4):941–947. PubMed PMID: 17761272. DOI:10.1016/j.jaci.2007.06.026
   PubMed Web of Science ®Google Scholar
• Berinert® [C1 Esterase Inhibitor (Human)]. For intravenous use. Freeze-dried powder for reconstitution. Initial U.S. Approval: 2009. FULL PRESCRIBING INFORMATION, 2016 cited 2017 Nov 16. Available from: http://labeling.cslbehring.com/PI/US/Berinert/EN/Berinert-Prescribing-Information.pdf.
   Google Scholar
• Craig T, Shapiro R, Vegh A, et al. Efficacy and safety of an intravenous C1-inhibitor concentrate for long-term prophylaxis in hereditary angioedema. Allergy Rhinol (Providence). 2017 Mar 01;8(1):13–19. PubMed PMID: 28381322; PubMed Central PMCID: PMC5380447. DOI:10.2500/ar.2017.8.0192
   PubMed Web of Science ®Google Scholar
• Longhurst H, Cicardi M, Craig T, et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. N Engl J Med. 2017 Mar 23;376(12):1131–1140. PubMed PMID: 28328347. DOI:10.1056/NEJMoa1613627
   PubMed Web of Science ®Google Scholar
• HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) For Subcutaneous Injection, Freeze-Dried Powder for Reconstitution. Initial U.S. Approval: 2017. FULL PRESCRIBING INFORMATION, 2017 cited 2017 Nov 16. Available from: https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM564335.pdf.
   Google Scholar
• CINRYZE® (C1 Esterase Inhibitor [Human]) for intravenous use, freeze -dried powder for reconstitution. Initial U.S. Approval: 2008. FULL PRECSRIBING INFORMATION, 2016 cited 2017 Nov 16. Available from: http://pi.shirecontent.com/PI/PDFs/Cinryze_USA_ENG.pdf.
   Google Scholar
• Moldovan D, Bernstein JA, Cicardi M. Recombinant replacement therapy for hereditary angioedema due to C1 inhibitor deficiency. PubMed PMID: 26250409 Immunotherapy. 2015;77:739–752. DOI:10.2217/imt.15.44
   PubMed Web of Science ®Google Scholar
• RUCONEST® (C1 esterase inhibitor [recombinant]) for intravenous use, lyophilized powder for reconstitution. FULL PRESCRIBING INFORMATION; cited 2017 Oct 15. Available from: https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM405634.pdf.
   Google Scholar
• Prematta M, Gibbs JG, Pratt EL, et al. Fresh frozen plasma for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol. 2007 Apr;98(4):383–388. PubMed PMID: 17458436. DOI:10.1016/S1081-1206(10)60886-1
   PubMed Web of Science ®Google Scholar
• Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol. 2010 Jul 28;6(1):24. PubMed PMID: 20667127; PubMed Central PMCID: PMC2921362. DOI:10.1186/1710-1492-6-24
   PubMedGoogle Scholar
• Cicardi M, Bork K, Caballero T, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an international working group. Allergy. 2012 Feb;67(2):147–157. PubMed PMID: 22126399.
   PubMed Web of Science ®Google Scholar
• Craig T, Aygoren-Pursun E, Bork K, et al. WAO guideline for the management of hereditary angioedema. World Allergy Organ J. 2012 Dec;5(12):182–199. PubMed PMID: 23282420; PubMed Central PMCID: PMC3651186.
   PubMedGoogle Scholar
• FIRAZYR® (icatibant) injection, for subcutaneous use. Initial U.S. Approval: 2011. FULL PRESCRIBING INFORMATION; 2015 Dec cited 2017 Oct 15. Available from: http://pi.shirecontent.com/PI/PDFs/Firazyr_USA_ENG.pdf.
   Google Scholar
• KALBITOR® (ecallantide) injection, for subcutaneous use. Initial U.S. Approval: 2009. FULL PRESCRIBING INFORMATION, 2015 cited 2017 Nov 16. Available from: http://www.shirecontent.com/PI/PDFs/Kalbitor_USA_ENG.pdf.
   Google Scholar
• Duffey H, Firszt R. Management of acute attacks of hereditary angioedema: role of ecallantide. J Blood Med. 2015;6:115–123. PubMed PMID: 25931832; PubMed Central PMCID: PMC4404974. DOI:10.2147/JBM.S66825
   PubMed Web of Science ®Google Scholar
• Lead programs of adverum biotechnologies, 2017 cited 2017 Oct 15. Available from: http://adverum.com/science/.
   Google Scholar
• Overview of KalVista’s drug discovery; 2017 cited 2017 Oct 15. Available from: http://www.kalvista.com/discovery-overview.html.
   Google Scholar
• Interim results of the drug development program of Verseon Corporation; 2017 Sep 25 cited 2017 Oct 2017 15. Available from: http://www.verseon.com/media-1/news/154-interim-results-2017.
   Google Scholar
• Farkas H, Reshef A, Aberer W, et al. Treatment effect and safety of icatibant in pediatric patients with hereditary angioedema. J Allergy Clin Immunol Pract. PubMed PMID: 28601641 Jun 07 2017. 10.1016/j.jaip.2017.04.010.
   PubMed Web of Science ®Google Scholar
• van Veen HA, Koiter J, Vogelezang CJ, et al. Characterization of recombinant human C1 inhibitor secreted in milk of transgenic rabbits. J Biotechnol. 2012 Dec 31;162(2–3):319–326. PubMed PMID: 22995741. DOI:10.1016/j.jbiotec.2012.09.005
   PubMed Web of Science ®Google Scholar
• Varga L, Farkas H. rhC1INH: a new drug for the treatment of attacks in hereditary angioedema caused by C1-inhibitor deficiency. Expert Rev Clin Immunol. 2011 Mar;7(2):143–153. PubMed PMID: 21426252. DOI:10.1586/eci.11.5
   PubMed Web of Science ®Google Scholar
• van Doorn MB, Burggraaf J, van Dam T, et al. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol. 2005 Oct;116(4):876–883. PubMed PMID: 16210064. DOI:10.1016/j.jaci.2005.05.019
   PubMed Web of Science ®Google Scholar
• Baker JW, Reshef A, Moldovan D, et al. Recombinant human C1-esterase inhibitor to treat acute hereditary angioedema attacks in adolescents. J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):1091–1097. PubMed PMID: 28202404. DOI:10.1016/j.jaip.2016.11.005
   PubMed Web of Science ®Google Scholar
• Farrell C, Hayes S, Relan A, et al. Population pharmacokinetics of recombinant human C1 inhibitor in patients with hereditary angioedema. Br J Clin Pharmacol. 2013 Dec;76(6):897–907. PubMed PMID: 23594263; PubMed Central PMCID: PMC3845313. DOI:10.1111/bcp.12132
   PubMed Web of Science ®Google Scholar
• Reshef A, Grivcheva-Panovska V, Kivity S, et al. Safety and efficacy of rhC1-INH for the treatment of HAE attacks in pediatric patients. Annual Scientific Meeting of American College of Allergy, Asthma & Immunology; 2015 Nov 5-9; San Antonio, TX: Ann Allergy Asthma Immunol; 2015.
   Google Scholar
• Bernstein JA, Relan A, Harper JR, et al. Sustained response of recombinant human C1 esterase inhibitor for acute treatment of hereditary angioedema attacks. Ann Allergy Asthma Immunol. 2017 Apr;118(4):452–455. PubMed PMID: 28284978. DOI:10.1016/j.anai.2017.01.029
   PubMed Web of Science ®Google Scholar
• Pharming announces positive data from paediatric clinical trial with RUCONEST® - Press release; 2017 Oct 2 cited 2017 Oct 15. Available from: https://www.pharming.com/pharming-announces-positive-data-from-paediatric-clinical-trial-with-ruconest/.
   Google Scholar
• Riedl MA, Grivcheva-Panovska V, Moldovan D, et al. Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial. Lancet. 2017 Sep 30;390(10102):1595–1602. PubMed PMID: 28754491. DOI:10.1016/S0140-6736(17)31963-3
   PubMed Web of Science ®Google Scholar
• Hack CE, Relan A, Van Amersfoort ES, et al. Target levels of functional C1-inhibitor in hereditary angioedema. Allergy. 2012;67(1):123–130.
   PubMed Web of Science ®Google Scholar
• CSL™ - R&D briefing presentation; 2014 Dec 3 cited 2017 Oct 15. Available from: http://www.csl.com.au/docs/805/134/Investor%20Briefing%20Presentation%20FINAL%202014.pdf.
   Google Scholar
• Cao H, Biondo M, Rayzman V, et al. Development and characterization of an anti-FXIIa monoclonal antibody for the treatment of hereditary angioedema. American Academy of Allergy, Asthma, and Immunology, annual meeting; 2015 Feb 20-24; Houston, TX: J Allergy Clin Immunol; 2015. J Allergy Clin Immunol. 2015;135:AB194.
   PubMed Web of Science ®Google Scholar
• Roberts A, Panousis C, Green T, et al. FXIIa-mediated kallikrein activity discriminates between HAE and normal plasma samples and is a pharmacodynamic marker for CSL312. 10th C1-inhibitor deficiency workshop; 2017 May 18-21; Budapest, Hungary: Allergy, Asthma & Clinical Immunology; 2017.
   Google Scholar
• Liu J, Qin J, Cooley B, et al. Reduction of hepatic factor XII expression in mice by ALN-F12 inhibits thrombosis without increasing bleeding risk. XXVI ISTH Congress and 63rd Annual SSC Meeting; 2017 Jul 8- 13;Berlin, Germany: Research and Practice in Thrombosis and Haemostasis.;2017
   Google Scholar
• Liu J, Qin J, Cooley B, et al. Reduction of hepatic factor XII expression in mice by ALN-F12 inhibits thrombosis without increasing bleeding risk - presentation held at ISTH 2017; cited 2017 Oct 15. Available from: http://www.alnylam.com/wp-content/uploads/2017/07/ALN-F12-ISTH2017-Presentation-Final.pdf.
   Google Scholar
• Akinc A, Liu J, Qin J, et al. An investigational RNAi therapeutic targeting factor XII (ALN-F12) for the treatment of hereditary angioedema. American Academy of Allergy, Asthma, and Immunology Annual Meeting; 2016 Mar 4-7; Los Angeles, CA: J Allergy Clin Immunol; 2016.
   Google Scholar
• Bhattacharjee G, Revenko AS, Crosby JR, et al. Inhibition of vascular permeability by antisense-mediated inhibition of plasma kallikrein and coagulation factor 12. Nucleic Acid Ther. 2013 Jun;23(3):175–187. PubMed PMID: 23582057.
   PubMed Web of Science ®Google Scholar
• Pipeline of preclinical and clinical studies by ionis pharmaceuticals; 2017 cited 2017 Oct 15. Available from: http://www.ionispharma.com/pipeline/.
   Google Scholar
• Lehmann A. Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opin Biol Ther. 2008 Aug 8;8:1187–1199. DOI:10.1517/14712598.8.8.1187
   PubMed Web of Science ®Google Scholar
• Farkas H, Varga L. Ecallantide is a novel treatment for attacks of hereditary angioedema due to C1 inhibitor deficiency. Clin Cosmet Investig Dermatol. 2011;4:61–68. PubMed PMID: 21760740; PubMed Central PMCID: PMC3133501. DOI:10.2147/CCID.S10322
   PubMedGoogle Scholar
• Advisory committee briefing document, Kalbitor® (ecallantide) for acute attacks of hereditary angioedema (BLA 125277) Jan 02, 2009 cited 2017 Nov 16. Available from: https://www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4413b1-03-Dyax.pdf.
   Google Scholar
• Cicardi M, Levy RJ, McNeil DL, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med. 2010 Aug 05;363(6):523–531. PubMed PMID: 20818887. DOI:10.1056/NEJMoa0905079
   PubMed Web of Science ®Google Scholar
• Levy RJ, Lumry WR, McNeil DL, et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol. 2010 Jun;104(6):523–529. PubMed PMID: 20568386. DOI:10.1016/j.anai.2010.04.012
   PubMed Web of Science ®Google Scholar
• Lumry WR, Bernstein JA, Li HH, et al. Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study. Allergy Asthma Proc. 2013 Mar-Apr;34(2):155–161. PubMed PMID: 23484891. DOI:10.2500/aap.2013.34.3653
   PubMed Web of Science ®Google Scholar
• MacGinnitie AJ, Davis-Lorton M, Stolz LE, et al. Use of ecallantide in pediatric hereditary angioedema. Pediatrics. 2013 Aug;132(2):e490–7. PubMed PMID: 23878046.
   PubMed Web of Science ®Google Scholar
• Bernstein JA, Qazi M. Ecallantide: its pharmacology, pharmacokinetics, clinical efficacy and tolerability. Expert Rev Clin Immunol. 2010 Jan;6(1):29–39. PubMed PMID: 20383888.
   PubMed Web of Science ®Google Scholar
• Kenniston JA, Faucette RR, Martik D, et al. Inhibition of plasma kallikrein by a highly specific active site blocking antibody. J Biol Chem. 2014 Aug 22;289(34):23596–23608. PubMed PMID: 24970892; PubMed Central PMCID: PMC4156074. DOI:10.1074/jbc.M114.569061
   PubMed Web of Science ®Google Scholar
• Chyung Y, Vince B, Iarrobino R, et al. A phase 1 study investigating DX-2930 in healthy subjects. Ann Allergy Asthma Immunol. 2014 Oct;113(4):460–6 e2. PubMed PMID: 24980392. DOI:10.1016/j.anai.2014.05.028
   PubMed Web of Science ®Google Scholar
• Banerji A, Busse P, Shennak M, et al. Inhibiting plasma kallikrein for hereditary angioedema prophylaxis. N Engl J Med. 2017 Feb 23;376(8):717–728. PubMed PMID: 28225674. DOI:10.1056/NEJMoa1605767
   PubMed Web of Science ®Google Scholar
• EU clinical trial register - HELP study™: a multicenter, randomized, double-blind, placebo-controlled efficacy and safety study to evaluate DX 2930 for long-term prophylaxis against acute attacks of hereditary angioedema (HAE), [ cited 2017 Nov 16]. Available from: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-003943-20.
   Google Scholar
• ClinicalTrials.gov - efficacy and safety study of DX-2930 to prevent acute angioedema attacks in patients with type I and type II HAE. 2017 cited 2017 Nov 16. Available from: https://clinicaltrials.gov/ct2/show/NCT02586805.
   Google Scholar
• Riedl MA, Bernstein JA, Craig T, et al. An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension. Clin Transl Allergy. 2017;7:36. PubMed PMID: 29043014; PubMed Central PMCID: PMCPMC5629784. DOI:10.1186/s13601-017-0172-9
   PubMed Web of Science ®Google Scholar
• EU clinical trials register - HELP study extension™: an open-label study to evaluate the long-term safety and efficacy of DX-2930 for prevention against acute attacks of hereditary angioedema (HAE), cited 2017 Nov 16. Available from: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005255-27.
   Google Scholar
• Cornpropst M, Dobo S, Collier J, et al. BCX7353, a potent inhibitor of plasma kallikrein, shows sustained maximal enzyme inhibition when dosed orally once daily: results from a phase I trial in healthy subjects. American Academy of Allergy, Asthma, and Immunology, Annual Meeting; 2016 Mar 4-7; Los Angeles, CA: J Allergy Clin Immunol; 2016.
   Google Scholar
• Cornpropst M, Dobo S, Collier J BCX7353, a potent inhibitor of plasma kallikrein, shows sustained maximal enzyme inhibition when dosed orally once daily: results from a phase I trial in healthy subjects - full version of poster presented at AAAAI 2016; cited 2017 Oct 15. Available from: http://www.biocryst.com/application/files/3014/7709/2261/AAAAI2016_BCX7353-101Poster.pdf.
   Google Scholar
• Avoralstat – oPuS-2 Results; 2016 Feb 8 cited 2017 Nov 16. Available from: http://files.shareholder.com/downloads/BCRX/5336066312x0x873686/8A78C027-983C-4219-A5F8-2B413B0D9C16/Avoralstat_OPuS-2_results_slides_8Feb16_FINAL.pdf.
   Google Scholar
• Chen X, Kotian P, Wilson R, et al. Preclinical characterization of BCX7353, an oral plasma kallikrein inhibitor, for the treatment of hereditary angioedema (HAE). American Academy of Allergy, Asthma, and Immunology, Annual Meeting; 2017 Mar 3-6; Atlanta, GA: J Allergy Clin Immunol; 2017.
   Google Scholar
• Chen X, Kotian P, Wilson R, et al. Preclinical Characterization of BCX7353, an Oral Plasma Kallikrein Inhibitor, for the Treatment of Hereditary Angioedema - Full version of a poster presentation held at the Annual Meeting of American Academy of Allergy, Asthma, and Immunology, 2017 Mar 3-6 cited 2017 Oct 15. Available from: http://www.biocryst.com/application/files/4014/8882/4138/BCX7353-AAAAI-2017_final-v2.pdf.
   Google Scholar
• BCX7353 – aPeX-1, final analysis results, 2017 Sep 5 cited 2017 Oct 15. Available from: http://files.shareholder.com/downloads/BCRX/5336066312x0x955610/9932121A-876F-4F1E-A4C6-C4173A296D63/APeX-1_Final_Analysis_Results.pdf.
   Google Scholar
• Kalfus I, McDonald A, Qian S Safety study of ATN-249, a new oral kallikrein inhibitor for hereditary angioedema. 10th C1-inhibitor deficiency workshop; 2017 May 18-21; Budapest, Hungary: Allergy, Asthma & Clinical Immunology; 2017.
   Google Scholar
• Kalfus I, McDonald A, Qian S Safety Study of ATN-249, A New Oral Kallikrein Inhibitor for Hereditary Angioedema - Full version of a presentation, held at the 10th C1-inhibitor deficiency workshop; 2017 May 18-21 cited 2017 Oct 15. Available from: http://attunepharma.com/assets/C1INH_Deficiency_Workshop_Oral_Presentation_20170521.pdf.
   Google Scholar
• Kalfus I, McDonald A, Qian S Potency, selectivity, and exposure evaluation of ATN-249, a new oral kallikrein inhibitor for hereditary angioedema. American Academy of Allergy, Asthma, and Immunology, Annual Meeting; 2017 Mar 3-6; Atlanta, GA: J Allergy Clin Immunol; 2017.
   Google Scholar
• Longhurst HJ, Farkas H, Craig T, et al. HAE international home therapy consensus document. Allergy Asthma Clin Immunol. 2010 Jul 28;6(1):22. PubMed PMID: 20667125; PubMed Central PMCID: PMC2922091. DOI:10.1186/1710-1492-6-22
   PubMedGoogle Scholar
• Schmaier AH, Cicardi M, Reshef A, et al. Abstracts from the 10th C1-inhibitor deficiency workshop. Allergy, Asthma Clin Immunol. 2017;13(S2). DOI:10.1186/s13223-017-0198-5
   Google Scholar